NFKB1 and cystic fibrosis: Tested in vitro on both CF and normal bronchial epithelial cells, the formulations were able to modulate both NF‐κB and MAPK/ERK pathways in absence of stimulation in bronchial epithelia, with higher effects in CF cells than in normal bronchial cells.